EIF4E — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1694516	1.00	20/20
SCHEMBL1694518	1.00	20/20
SCHEMBL1694619	1.00	20/20
SCHEMBL1694623	1.00	20/20
SCHEMBL1694624	1.00	20/20
SCHEMBL1694626	1.00	20/20
SCHEMBL1694823	1.00	20/20
SCHEMBL1694826	1.00	20/20
SCHEMBL1694863	1.00	20/20
SCHEMBL1694869	1.00	20/20
SCHEMBL1694901	1.00	20/20
SCHEMBL1694672	0.62	20/20
SCHEMBL1694680	0.62	20/20
SCHEMBL1208143	0.70	19/20
SCHEMBL1206979	0.65	18/20
SCHEMBL1695358	0.52	18/20
SCHEMBL1695363	0.52	18/20
SCHEMBL1197775	0.49	18/20
SCHEMBL1198911	0.49	18/20
SCHEMBL695216	0.53	17/20

Clinical trials — most relevant to EIF4E by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer	PHASE3	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery	PHASE2	WITHDRAWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)	nan	RECRUITING
Quantification of GADD34 Expression in RA	nan	COMPLETED
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF4E binder may also engage these)

Protein	Name	Similarity
P63074	—	1.000	P63074 →
P63073	—	1.000	P63073 →
Q9N0T5	—	0.998	Q9N0T5 →
P29338	—	0.997	P29338 →
P48597	—	0.972	P48597 →
Q9DFS6	—	0.969	Q9DFS6 →
Q2KHU8	—	0.935	Q2KHU8 →
P81795	—	0.932	P81795 →
P20461	—	0.931	P20461 →
P41091	—	0.930	P41091 →
Q4R5I3	—	0.930	Q4R5I3 →
Q9GKK5	—	0.929	Q9GKK5 →
Q9Z0N1	—	0.929	Q9Z0N1 →
Q13888	—	0.929	Q13888 →
F1QGW6	—	0.929	F1QGW6 →
RPL22	Large ribosomal subunit protein eL22	0.928	landscape →
C9WPN6	—	0.928	C9WPN6 →
P67985	—	0.927	P67985 →
P67984	—	0.927	P67984 →
Q32KM1	—	0.926	Q32KM1 →
Q98TF8	—	0.926	Q98TF8 →
P83887	—	0.926	P83887 →
Q5ZMS3	—	0.926	Q5ZMS3 →
TSG101	Tumor susceptibility gene 101 protein	0.926	landscape →
Q0VCD2	—	0.925	Q0VCD2 →
Q4W5Z4	—	0.925	Q4W5Z4 →
P23258	—	0.925	P23258 →
Q2VIR3	—	0.925	Q2VIR3 →
P83888	—	0.925	P83888 →
Q5R797	—	0.925	Q5R797 →